Find information on thousands of medical conditions and prescription drugs.

Filgrastim

Filgrastim is a granulocyte colony-stimulating factor (G-CSF) analog used to stimulate the proliferation and differentiation of granulocytes. It is produced by recombinant DNA technology and is marketed under the trade name "Neupogen." The gene for human granulocyte colony-stimulating factor is inserted into the genetic material of Escherichia coli. The G-CSF then produced by E. coli is only slightly different from G-CSF naturally made in humans. more...

Home
Diseases
Medicines
A
B
C
D
E
F
Captagon
Famohexal
Famotidine
Faslodex
Faslodex
Fasoracetam
Felbamate
Felbatol
Felodipine
Felypressin
Femara
Femara
Fempatch
Femring
Fenfluramine
Fenofibrate
Fentanyl
Fexofenadine
Filgrastim
Filipin
Finasteride
Fioricet
Fiorinal
Flagyl
Flarex
Flavoxate
Flecainide
Flexeril
Flomax
Flonase
Flovent
Floxuridine
Fluacizine
Flucloxacillin
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flumazenil
Flunisolide
Flunitrazepam
Fluocinonide
Fluohexal
Fluorometholone
Fluorouracil
Fluoxetine
Fluphenazine
Flurazepam
Flutamide
Fluticasone
Fluvastatin
Fluvoxamine
FML
Focalin
Folic acid
Follutein
Fomepizole
Formoterol
Fortamet
Fortovase
Fosamax
Fosinopril
Fosinoprilat
Fosmidomycin
Fosphenytoin
Frova
Frovatriptan
Frusehexal
Fulvestrant
Fumagillin
Furazolidone
Furosemide
Furoxone
Fusafungine
Fusidic acid
Fuzeon
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Therapeutic uses

Filgrastim is used to treat neutropenia (a low number of neutrophils), stimulating the bone marrow to increase production of neutrophils. Causes of neutropenia include chemotherapy and bone marrow transplantation. Filgrastim is also used to increase the number of myeloid stem cells before collection by leukapheresis.

Contraindications

Filgrastim should not be used in patients with known hypersensitivity to E. coli-derived proteins.

Adverse effects

The most commonly observed adverse effect is mild-to-moderate bone pain after repeated administration and local skin reactions at the site of injection.

Read more at Wikipedia.org


[List your site here Free!]


Peripheral stem cell transplantation plus monoclonal antibody therapy in treating patients with high-risk hematologic cancer, refractory breast or kidney
From Journal of Drugs in Dermatology, 11/1/04

This study is currently recruiting patients.

Sponsored by Duke Comprehensive Cancer Center National Cancer Institute (NCI)

Peripheral stem cell transplantation replaces immune cells that were destroyed by chemotherapy which was used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Treatment of the cells with a monoclonal antibody may prevent this from happening. The purpose of this phase II trial is to study the effectiveness of peripheral stem cell transplantation plus monoclonal antibody therapy in treating patients who have high-risk hematologic cancer, refractory breast or kidney cancer, or melanoma.

Study ID Numbers: CDR0000067374; DUMC-1340-99-7; NCI-G99-1617

ClinicalTrials.gov Identifier: NCT00004143

COPYRIGHT 2004 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2005 Gale Group

Return to Filgrastim
Home Contact Resources Exchange Links ebay